CSIMarket
 
Ekso Bionics Holdings Inc   (NASDAQ: EKSO)
Other Ticker:  
 
 
Price: $0.5740 $0.02 3.423%
Day's High: $0.5748 Week Perf: 9.33 %
Day's Low: $ 0.54 30 Day Perf: -17.31 %
Volume (M): 193 52 Wk High: $ 2.16
Volume (M$): $ 111 52 Wk Avg: $1.09
Open: $0.56 52 Wk Low: $0.47



 Market Capitalization (Millions $) 12
 Shares Outstanding (Millions) 20
 Employees 120
 Revenues (TTM) (Millions $) 16
 Net Income (TTM) (Millions $) -11
 Cash Flow (TTM) (Millions $) -2
 Capital Exp. (TTM) (Millions $) 0

Ekso Bionics Holdings Inc
Ekso Bionics Holdings Inc is a leading company in the field of exoskeleton technology. They design and develop wearable robotic devices that assist individuals with mobility impairments. Their exoskeletons are designed to enable individuals with lower limb paralysis or weakness to stand, walk, and regain their independence. The company's products have been used in the healthcare industry and also have potential applications in industries such as construction and manufacturing. Ekso Bionics is dedicated to improving the quality of life for individuals with limited mobility through their innovative exoskeleton technology.


   Company Address: 101 Glacier Point, Suite A San Rafael 94901 CA
   Company Phone Number: 984-1761   Stock Exchange / Ticker: NASDAQ EKSO


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
LFWD        40.71% 
• View Complete Report
   



Management Announcement

Ekso Bionics Sets the Stage for Record Revenues in Q4 2024 Amidst Strategic Financing Initiatives

Published Mon, Jan 13 2025 1:01 PM UTC

In an impressive display of perseverance and innovation, Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) has made significant strides in its financial trajectory and product development. The company recently reported preliminary results indicating a remarkable upward trend in revenues for the fourth quarter of 2024, projecting an all-time high that positions it as a leader in the...

Financing Agreement

Ekso Bionics Raises $6 Million to Empower the Future of Mobility through Exoskeleton Innovation,

Published Fri, Aug 30 2024 2:43 AM UTC

Ekso Bionics: Revolutionizing Exoskeleton Technology through a $6.0 Million Public Offering
San Rafael, California - Leading exoskeleton technology company, Ekso Bionics Holdings, Inc. (Nasdaq: EKSO), recently announced the pricing of a highly anticipated underwritten public offering. The offering, which includes a total of 6,000,000 units and pre-funded units, is expect...

Management Announcement

Ekso Bionics Makes Strides in Exoskeleton Technology with CMS Reimbursement and Accessible Healthcare Program,

Published Tue, Aug 20 2024 12:00 PM UTC


Ekso Bionics Makes Strides with CMS Reimbursement and Launches EksoHealth Personal Program
Ekso Bionics Holdings Inc, a leading exoskeleton technology company, has recently announced the receipt of initial reimbursement from the Centers for Medicare & Medicaid Services (CMS) for its Ekso Indego Personal exoskeleton. This marks a significant milestone for the company...

Partnership

title Exoskeletons Revolutionize Rehabilitation Collaborative Leap Towards Enhanced Patient Lives

Published Tue, Jun 25 2024 12:01 PM UTC

Advancing Rehabilitation Technology: Ekso Bionics and Shepherd Center Form Research PartnershipIn a bid to revolutionize rehabilitation and enhance patient outcomes, Ekso Bionics, a leading developer of exoskeleton technology, has announced a promising research partnership with the renowned Shepherd Center. The collaboration aims to expand the use of EksoNR and Ekso Indego d...

Ekso Bionics Holdings Inc

Ekso Bionics Holdings Inc Makes Major Strides in Revolutionizing Mobility and Improving Lives

Exciting News for Ekso Bionics: Revolutionizing Mobility and Improving Lives
Investors in the stock market have reason to rejoice as Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) continues to make strides in its mission to enhance mobility and quality of life for individuals with spinal cord injuries. The latest development comes in the form of a significant milestone achieved by Ekso Bionics - the final payment determination for Medicare reimbursement of the Ekso Indego Personal exoskeleton from the Centers for Medicare & Medicaid Services (CMS).
With the CMS establishing a reimbursement rate of $91,031.93 for the Ekso Indego Personal, effective from April 1, 2024, Ekso Bionics is poised for even greater success. This validates the company's position as an industry leader and innovator in exoskeleton technology, which will undoubtedly have a positive impact on future financial results.







Ekso Bionics Holdings Inc's Segments
Ekso Health    127.36 % of total Revenue
Ekso Works    1.31 % of total Revenue
Product    97.23 % of total Revenue
Product Ekso Health    96.48 % of total Revenue
Product Ekso Works    0.75 % of total Revenue
Service    21.53 % of total Revenue
Service Ekso Health    21.53 % of total Revenue
Subscription    3.83 % of total Revenue
Subscription Ekso Health    3.83 % of total Revenue
Product and Service Other    6.08 % of total Revenue
Product and Service Other Ekso Health    5.52 % of total Revenue
Product and Service Other Ekso Works    0.56 % of total Revenue
UNITED STATES    58.49 % of total Revenue
Americas Other    0.56 % of total Revenue
Americas    59.05 % of total Revenue
FRANCE    33.25 % of total Revenue
POLAND    3.52 % of total Revenue
EMEA Other    16.73 % of total Revenue
EMEA    53.51 % of total Revenue
HONG KONG    6.67 % of total Revenue
APAC Other    9.44 % of total Revenue
Asia Pacific    16.11 % of total Revenue





Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com